Cover Image
市場調查報告書

Parion Sciences, Inc.:產品平台分析 (2014年)

Parion Sciences, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321350
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Parion Sciences, Inc.:產品平台分析 (2014年) Parion Sciences, Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月16日 內容資訊: 英文 25 Pages
簡介

Parion Sciences, Inc.是製藥公司。正在開發囊狀纖維化症,慢性阻塞性肺病,支氣管擴張症等肺部疾病的治療藥。目前正在開發用於治療肺,口,鼻子,消化道所用的ENaC阻斷劑。此外也在開發緩和慢性口內乾燥症的漱口水,及乾眼症用的化合物。原公司名為CYFI, Inc.,總公司位於美國北卡羅萊那州的Durham。

本報告提供Parion Sciences, Inc.調查分析,提供您企業概要,研究·開發概要,開發平台分析,開發中產品的概要,藥物簡介,最新趨勢和計劃等相關的系統性資訊。

目錄

Parion Sciences, Inc.的概述

  • Parion Sciences, Inc.概要
  • 主要資訊
  • 企業資料

Parion Sciences, Inc.:研究·開發概要

  • 主要的治療領域

Parion Sciences, Inc.:開發平台分析

  • 各開發階段的開發中產品
  • 開發中產品:單獨療法

Parion Sciences, Inc.:開發中產品的概要

  • 臨床階段的開發中產品
  • 初期階段的開發中產品

Parion Sciences, Inc.:藥物簡介

  • P-1037
  • P-321
  • P-552
  • Drug for Respiratory Diseases
  • Small Molecule to Activate CFTR Protein for Cystic Fibrosis

Parion Sciences, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Parion Sciences, Inc.:開發平台的最新趨勢

Parion Sciences, Inc.:暫停中的計劃

Parion Sciences, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Parion Sciences, Inc.:所在地

  • 總公司

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07588CDB

Summary

Global Markets Direct's, 'Parion Sciences, Inc. - Product Pipeline Review - 2015', provides an overview of the Parion Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Parion Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Parion Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Parion Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Parion Sciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate Parion Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Parion Sciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Parion Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Parion Sciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Parion Sciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Parion Sciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Parion Sciences, Inc. Snapshot
    • Parion Sciences, Inc. Overview
    • Key Information
    • Key Facts
  • Parion Sciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Parion Sciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Parion Sciences, Inc. - Pipeline Products Glance
    • Parion Sciences, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Parion Sciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Parion Sciences, Inc. - Drug Profiles
    • P-321
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Respiratory Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate CFTR Protein for Cystic Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Parion Sciences, Inc. - Pipeline Analysis
    • Parion Sciences, Inc. - Pipeline Products by Target
    • Parion Sciences, Inc. - Pipeline Products by Route of Administration
    • Parion Sciences, Inc. - Pipeline Products by Molecule Type
    • Parion Sciences, Inc. - Pipeline Products by Mechanism of Action
  • Parion Sciences, Inc. - Recent Pipeline Updates
  • Parion Sciences, Inc. - Dormant Projects
  • Parion Sciences, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GS-9411
  • Parion Sciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Parion Sciences, Inc., Key Information
  • Parion Sciences, Inc., Key Facts
  • Parion Sciences, Inc. - Pipeline by Indication, 2015
  • Parion Sciences, Inc. - Pipeline by Stage of Development, 2015
  • Parion Sciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Parion Sciences, Inc. - Out-Licensed Products in Pipeline, 2015
  • Parion Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Parion Sciences, Inc. - Phase I, 2015
  • Parion Sciences, Inc. - Preclinical, 2015
  • Parion Sciences, Inc. - Pipeline by Target, 2015
  • Parion Sciences, Inc. - Pipeline by Route of Administration, 2015
  • Parion Sciences, Inc. - Pipeline by Molecule Type, 2015
  • Parion Sciences, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Parion Sciences, Inc. - Recent Pipeline Updates, 2015
  • Parion Sciences, Inc. - Dormant Developmental Projects,2015
  • Parion Sciences, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Parion Sciences, Inc. - Pipeline by Top 10 Indication, 2015
  • Parion Sciences, Inc. - Pipeline by Stage of Development, 2015
  • Parion Sciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Parion Sciences, Inc. - Pipeline by Top 10 Target, 2015
  • Parion Sciences, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Parion Sciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Parion Sciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top